Help
Subscribe


GastroHep.com - the global online resource for all aspects of gastroenterology, hepatology and endoscopy

 17 February 2018

Advanced search
GastroHep.com - the global online resource for all aspects of gastroenterology, hepatology and endoscopy Profile of Roy Pounder

Home

News  
Journals
Review Articles
Slide Atlas
Video Clips
Online Books
Advanced Digestive Endoscopy
Classical Cases
Conference Diary
PubMed
International GH Links
USA GH Links
National GH Links
National GI Societies
Other Useful Links




Emails on Gastroenterology and Hepatology
the National AIDS Treatment Advocacy Project
Visit the gastroenterology section of the EUMS

News

c-Myc overexpression associated with cancer in Barrett's

c-Myc overexpression is strongly associated with the metaplasia-dysplasia-adenocarcinoma sequence in the esophagus, reports the latest Diseases of the Esophagus.

News image

fiogf49gjkf04

Barrett's esophagus develops as a result of a severe esophageal mucosa injury from gastroesophageal reflux.

Barrett's esophagus is a premalignant lesion and plays an important role in the development of esophageal adenocarcinoma.

Dr Schmidt and colleagues from Brazil determined the expression of the proto-oncogene c-Myc in patients with Barrett's esophagus, and esophageal adenocarcinoma.

The research team evaluated the prevalence of such expression in relation to the metaplasia-dysplasia-adenocarcinoma sequence.

c-Myc overexpression occurred in 37% of Barrett's esophagus
Diseases of the Esophagus

The team identified several genetic alterations in the process that transforms a normal cell into a tumorous one.

In the development of human tumors, one of the most important genes is the proto-oncogene c-Myc.

The researchers then determined c-Myc protein expression by immunohistochemical analysis in 4 different groups.

The team reported that there were 31 patients with normal tissue, and 43 patients with Barrett's esophagus without dysphasia.

The team also identified 11 patients with dysplasia in Barrett's esophagus, and 37 patients with esophageal adenocarcinoma.

The material was obtained from esophageal biopsies or the dissection of patient esophagectomy specimens.

The researchers analyzed demographic and endoscopic data that included sex, age, race and intestinal metaplasia extension.

In addition the team assessed morphologic and histopathologic tumor characteristics.

The research team evaluated deep tumor invasion, lymph node status, and tumor differentiation.

The c-Myc expression was assessed using the Immunoreactive Scoring System.

The team found overexpression of c-Myc in only 10% of normal tissue specimens.

c-Myc overexpression occurred in 37% of Barrett's esophagus patients, and 46% of Barrett's esophagus patients with dysphasia.

In adenocarcinoma samples, the team observed c-Myc over expression in 73%.

There was no significant statistical difference among these groups.

The research team identified no correlation when the c-Myc expression was compared with morphologic and histologic tumor features or endoscopic data.

However, linear correlation of c-Myc overexpression along the metaplasia-dysplasia-adenocarcinoma sequence was observed.

Dr Schmidt's team concluded, "This study demonstrates a significant increase in the expression of c-Myc in Barrett's esophagus dysplasia and adenocarcinoma in relation to the control group.

"We also found a linear progression of this gene expression in this sequence."

"These results point out the importance of this marker in the development of esophageal adenocarcinoma from Barrett's esophagus."

Dis Esophagus 2007:20(3): 212-6
24 May 2007

Go to top of page Email this page Email this page to a colleague

 16 February 2018 
Undetected celiac in the elderly
 16 February 2018 
Inflammatory bowel diseases are global diseases
 16 February 2018 
Fructans induce non-celiac gluten sensitivity
 15 February 2018 
Oral direct-acting antiviral treatment for Hep C virus genotype 1
 15 February 2018 
NSAIDS and GI damage
 15 February 2018 
Primary vs secondary surgery for the presence of lymph node metastasis
 14 February 2018 
Management of hemorrhoids in the USA
 14 February 2018 
Predicting adenoma detection rate
 14 February 2018 
Normal bowel frequency characterization in the USA 
 13 February 2018 
Prebiotics improve endothelial dysfunction
 13 February 2018 
Personalising treatment options for IBS
 13 February 2018 
Diagnostic criteria for a Rome IV functional gastrointestinal disorders
 12 February 2018 
Visceral hypersensitivity and functional GI disorders
 12 February 2018 
Depression and aggressive IBD
 12 February 2018 
Variability in interpretation of endoscopic findings impacts patient management
 09 February 2018 
Treatment of choice for anastomotic stricture in IBD
 09 February 2018 
PRO measurement information system 
 09 February 2018 
Overall disease severity indices for IBD
 08 February 2018 
Prediction of endoscopically active disease

 08 February 2018 
Steroid-refractory acute severe ulcerative colitis
 08 February 2018 
Decision aid used by IBD patients
 07 February 2018 
Ursodeoxycholic acid combined with bezafibrate for itching
 07 February 2018 
Change in microbiome in gastritis vs gastric carcinoma
 07 February 2018 
Colorectal cancer and primary sclerosing cholangitis-IBD
 06 February 2018 
Risk of death after liver transplantation
 06 February 2018 
Crohn’s disease vs refractory pouchitis
 06 February 2018 
Support for functional dyspepsia symptom diary
 05 February 2018 
Helicobacter spp influence on GI tract 
 05 February 2018 
No link found between severe reflux and all-cause mortality 
 05 February 2018 
Psychological distress in PPI non-responders
 02 February 2018 
Assessing psychosexual impact of IBD
 02 February 2018 
Decrease in overall mortality with cholera vaccination
 02 February 2018 
Diagnostic performance of fecal immunochemical tests
 01 February 2018 
Screening frequency with family histories of colorectal cancer
 01 February 2018 
IBD and sport participation
 01 February 2018 
Life with a stoma 
 31 January 2018 
Aprepitant and gastroparesis 
 31 January 2018 
Anesthesia risk in colonoscopy
 31 January 2018 
GED-0301 for Crohn's Disease
 30 January 2018 
Intestinal dysbiosis and allergic diseases in infants
 30 January 2018 
Fructans and IBS symptoms in children
 29 January 2018 
Dosing calculator for therapy optimization in IBD
 29 January 2018 
Glecaprevir–pibrentasvir for in HCV
 29 January 2018 
Food allergen injections in eosinophilic esophagitis
 29 January 2018 
Reliability of the IBD index
 26 January 2018 
Tofacitinib vs biological therapies for ulcerative colitis
 26 January 2018 
Optimizing selection of biologics in IBD
 26 January 2018 
Nutritional risk and laparoscopic-assisted gastrectomy outcomes
 25 January 2018 
Patient-reported outcome measure for functional dyspepsia
 25 January 2018 
Predicting intra-abdominal infections after colorectal surgery
 25 January 2018 
Predictors of gastric cancer risk
 24 January 2018 
Risk factors underlying previously undiagnosed cirrhosis
 24 January 2018 
Ethnicity influences phenotype in IBD
 24 January 2018 
Bariatric surgery vs medical obesity treatment
 23 January 2018 
Atrophic gastritis after H. pylori eradication
 23 January 2018 
Ectopic pregnancy in women with IBD
 23 January 2018 
Celiac disease in IBS in the USA
 22 January 2018 
Improving symptoms in GERD
 22 January 2018 
Costs of biologic therapies for IBD in the USA
 22 January 2018 
Western vs Asian guidelines for colon cancer management

Blackwell Publishing


GastroHep.com is a Blackwell Publishing registered trademark
© 2018 Wiley-Blackwell and GastroHep.com and contributors
Privacy Statement
Disclaimer
About Us